These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://tasneemybgs730415.arwebo.com/61435360/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide